Treatment of Chronic Hepatitis B with Tenofovir

Background:Tenofovir is among the first-line treatments for chronic hepatitis B (CHB) virus infection. We evaluated the efficacy of Tenofovir in the treatment of Iranian adult patients with CHB. Methods: In a retrospective study, we evaluated ۱۵۴ HBsAg positive patients referred to Sadoughi hospital in Yazd-Iran for treatment during ۲۰۰۹-۲۰۱۴. Forty-five patients were naive and ۱۰۹ patients were treated previously with lamivudine or interferon. HBs Ag, HBeAg, HBeAb and quantitative HBV- DNA PCR were measured. The patients with HBV DNA >۱۰,۰۰۰ copy per ml in precore mutant and HBV DNA>۱۰۰,۰۰۰ copy per ml in wild type and ALT >two times of normal value were included. Tenofovir disoproxil fumarate ۳۰۰ mg was administered and continued for three years. Data were analyzed using SPSS۱۹. Results: We enrolled ۱۵۴ (۱۰۹ males ۴۵ female) patients. Mean age of patients was ۴۱± ۸ years (۱۸-۵۸ year old). Forty-five of them were naive and the rest had previously experienced treatment. In this study, ۱۱۳ of patients were of wild type and ۴۱ patients were precore mutant variant. In wild type patients, ۲۵ ones were naive and in precore mutant subtype, ۲۰ patients were naive. HBsAg disappeared in ۵ patients (۳.۲ percent). Forty one of ۴۵ patients in the naive group (۹۱ percent) and ۹۶ of ۱۰۹ patients in the previously treated group (۸۸ percent) were cured. AST and ALT levels decreased in over ۸۰ percent of patients and means of AST and ALT levels showed more decrease in naive and precore mutant subgroups. Serum AST and ALT and HBV DNA were higher in the wild type group than in the precore mutant group. Seroconversion occurred in ۶۹ out of ۱۱۳ patients at the end of the study. Conclusion: Treatment response rate to Tenofovir in Iranian patients with CHB was high. Tenofovir could be recommended as the first-line therapy of chronic HBV infection in Iran.

Keywords:

Chronic hepatitis B , Tenofovir , Therapy Efficacy , Seroconvertion